A new test can identify patients with multiple myeloma (MM) who have a high-risk genetic profile as well as multiple chromosomal abnormalities. In this subgroup of patients with ultra-high-risk MM, disease progression is increased, survival is very poor, and it is unlikely that patients will respond to a commonly used maintenance therapy, British researchers report. Read more...Continue Reading

The COVID-19 pandemic continues to put a strain on healthcare delivery around the world. In this environment, haematologists are adapting their approach to treating multiple myeloma to minimise the risk to their patients. Last Thursday, Professor Miles Prince hosted a webcast to explore the issues surrounding management of patients during this challenging time. Joining him...Continue Reading